Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
View Patent ↗Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
1. A method for the treatment of Arenavirus infection, comprising administering in a therapeutically effective amount to a mammal in need thereof, a compound of formula I below:
wherein
n is an integer from 0-6;
m is an integer from 0-1;
p is an integer from 0-1;
R 1 is selected from the group consisting of H and alkyl;
R 2 is selected from the group consisting of substituted or unsubstituted phenyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted branched alkyl, and substituted or unsubstituted unsaturated cycloheteroalkyls;
or where R 1 and R 2 combine together to form a substituted or unsubstituted C 4-10 cyclic saturated heteroalkyl;
R 3 is selected from the group consisting of H and alkyl;
R 4 is selected from the group consisting of H and alkyl; and
wherein the compound of formula I is selected from the group consisting of:
1-[1,1-bis(trifluoromethyl)propyl]-3-[(2,4,6-trimethylphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(4-tert-butylphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(2,5-dimethoxyphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-(2-naphthylsulfonylamino)urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(4-isopropylphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(5-chloro-2-methoxy-phenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(2-phenylphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(3,4-dichlorophenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(4-bromophenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[[4-(difluoromethoxy)phenyl]sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(3,5-dimethylphenyl)sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-(1-naphthylsulfonylamino)urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)sulfonylamino]urea;
1-[[2,5-bis(2,2,2-trifluoroethoxy)phenyl]sulfonylamino]-3-[1,1-bis(trifluoromethyl)propyl]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[[4-(thiadiazol-4-yl)phenyl]sulfonylamino]urea;
1-[1,1-bis(trifluoromethyl)propyl]-3-[(5-bromo-2-methoxy-phenyl)sulfonylamino]urea; and
1-[1,1-bis(trifluoromethyl)propyl]-3-[(4-phenylphenyl)sulfonylamino]urea.
2. The method of claim 1 , wherein the compound is 1-[1,1-bis(trifluoromethyl)propyl]-3-[[4-(thiadiazol-4-yl)phenyl]sulfonylamino]urea.
3. The method of claim 1 , wherein the mammal is a human.
4. The method of claim 1 , wherein the Arenavirus is selected from the group consisting of Junin, Machupo, Guanavito, Sabia, and Lassa.